ORPHAN DRUG STATUS DESIGNATION

 Advanced Medical Projects has obtained the Orphan Drug Status for GESTELMIR in November 2012 against dyskeratosis congenita. This is a disease caused by low telomerase activity leading to bone marrow failure and sometimes to cancer. Most patients have an average life expectancy of 14 to 16 years. Our company is designing the clinical trials to begin in Q4 of 2013 taking place in the US and Spain. This will be a FIRST-IN-MAN drug since there is no actual treatment.

Advanced Medical Projects

  We focus on development of new therapies against diseases where cells age too fast, mainly because of chromosome instability. AMP is the first company to develop a patented family of human peptides as a therapeutic product candidate able to increase Telomerase activity in senescent cells, in vivo. Telomerase is a molecular complex of very difficult biomedical manipulation; its role is to maintain the length of telomeres, which are special DNA sequences located at the end of chromosomes to protech them from degradation.

  As cells divide in normal life, telomeres become shorter and shorter, and eventually the cell becomes senescent. Abnormal telomere shortening means abnormal aging and also increase of mutations that may cause cancer. So low Telomerase activity is a key factor in cancer and abnormally fast aging.

  Our patented GSE24-2 peptides have already demonstrated in vitro potential in several diseases, including cancer, Diskeratosis Congenita, Werner Syndrome, Idiopathic Pulmonary Fibrosis, etc. GSE24-2 is currently in preclinical studies, in animal models, and based on the results generated so far we hope to reach very soon studies in human patients. Currently, we are also developing new administration platforms for these peptides, able to guarantee safety and correct dosage.